60例卵巢癌合并腹水临床分析  

Clinical Analysis of 60 Cases of Ovarian Carcinoma with Asites

作　　者：牛春莲 岳晓丽[1] 李红宇[1] 

机构地区：[1]安阳市肿瘤医院妇科

出　　处：《河南肿瘤学杂志》1997年第5期367-368,共2页Henan Journal of Oncology

摘　　要：1978年1月～1990年1月，我院对60例卵巢上皮癌合并腹水进行腹腔化疗，其中Ⅰ期19例，Ⅱ期14例，Ⅲ期27例。初治时先行手术治疗，确定临床分期及病理分类，之后给予腹腔化疗。所用药物为：MMC6mg＋5－Fu500～750mg＋AT125840～60mg，每周用药1次。60例化疗2～13次，平均5次。化疗4次以上3年5年存活率明显高于化疗3次以下者。提示多疗程腹腔化疗能提高卵巢癌合并腹水的生存率。From January 1978 to January 1990,60 cases of ovarian epithelial carcinoma including 19 cases of stage Ⅰ, 14 cases of stage Ⅱ, and 27 cases of stages Ⅲ were treated with intraperineal chemotherapy.Each stage was first operated to confirm clinical stages and pathelogic types,then beated with intraperitoneal chemotheropy. The drugs were MMC 6mg, 5 - FU 500 ～ 750mg and AT1258 40 ～ 60mg. We used them once a wddk. The patients received the treatment from 2 to 13 times and had 5 times on an average.The survival rates of 3 to 5 years of the patients being treated more than 4 times were much higher than those of the Patients being treated less than 3 times. It suggests that multipule courses of intraperitoneal chemotherapy can improve the survival late of Patients with ovarian carcinoma with ascites.

关 键 词：卵巢上皮癌 腹水 腹腔化疗 

分 类 号：R737.310.5[医药卫生—肿瘤]